论文部分内容阅读
白血病细胞对阿糖胞苷(Ara-C)的耐药与胞苷脱氨酶浓度的增加或脱氧胞苷激酶浓度的降低有关。尽管用常规剂量的本品治疗非淋巴细胞白血病获得较高缓解率,但大多数患者最终死于耐药性。本文报道给患者投用大剂量本品以克服耐药性的研究结果。受试者为14例非淋巴细胞白血病和1例Burk-kit’s淋巴瘤的白血病患者,肝肾功能均正常。每12hr静脉输注阿糖胞苷3g/m~2(输注1hr),共12次。另外
Resistance of leukemic cells to cytarabine (Ara-C) is associated with either an increase in cytidine deaminase concentration or a decrease in deoxycytidine kinase concentration. Although the treatment of non-lymphocytic leukemia with conventional doses to obtain a higher response rate, but most patients eventually died of drug resistance. This article reports to patients using large doses of this product to overcome the resistance of the research results. Subjects were 14 non-lymphocytic leukemia and 1 Burk-kit’s lymphoma in patients with leukemia, liver and kidney function were normal. Each 12hr intravenous infusion of cytarabine 3g / m ~ 2 (infusion 1hr), a total of 12 times. In addition